Related Experiment Video
Updated: Mar 23, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
[JAK2 inhibitors]
Juan Carlos Hernández Boluda1, Montse Gómez1, Ariadna Pérez1
1Servicio de Hematología, Hospital Clínico Universitario, Valencia, España.
Abstract:
Pharmacological inhibition of the kinase activity of JAK proteins can interfere with the signaling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms. JAK inhibitors may, therefore, be useful to treat malignancies as well as inflammatory or immune disorders. Currently, the most significant advances have been made in the treatment of myelofibrosis, where these drugs may lead to a remarkable improvement in the control of hyperproliferative manifestations. However, available data suggest that this treatment is not curative of myelofibrosis. In general, JAK2 inhibition induces cytopaenias, with this being considered a class side-effect. By contrast, the extrahaematologic toxicity profile varies significantly among the different JAK inhibitors. At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its therapeutic activity as well as reducing haematologic toxicity.
Insights
Janus kinase (JAK) inhibitors show promise for treating myeloproliferative neoplasms and inflammatory conditions by blocking the JAK-STAT pathway. While effective for myelofibrosis symptom control, they are not curative and can cause cytopenias.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Janus kinase (JAK) proteins are crucial in cytokine signaling and the JAK-STAT pathway.
- Constitutive activation of the JAK-STAT pathway is implicated in certain malignancies, such as chronic myeloproliferative neoplasms.
- JAK inhibitors offer a potential therapeutic strategy for malignancies and inflammatory/immune disorders.
Purpose of the Study:
- To review the role of JAK inhibitors in treating malignancies and immune disorders.
- To highlight advances in myelofibrosis treatment using JAK inhibitors.
- To discuss the efficacy, limitations, and side effects of JAK inhibitors.
Main Methods:
- Review of current literature and clinical trial data on JAK inhibitors.
- Analysis of the mechanism of action of JAK inhibitors on the JAK-STAT pathway.
- Evaluation of therapeutic outcomes and toxicity profiles of JAK inhibitors, particularly in myelofibrosis.
Main Results:
- JAK inhibitors effectively interfere with cytokine signaling and block the JAK-STAT pathway.
- Significant improvements in controlling hyperproliferative manifestations have been observed in myelofibrosis patients treated with JAK inhibitors.
- JAK2 inhibition commonly leads to cytopenias as a class side-effect, though extra-hematologic toxicity varies among inhibitors.
Conclusions:
- JAK inhibitors represent a valuable therapeutic option for myeloproliferative neoplasms and inflammatory diseases.
- Current JAK inhibitor therapy, while improving symptoms, is not curative for myelofibrosis.
- Ongoing clinical trials are exploring combination therapies to enhance efficacy and mitigate hematologic toxicity.
More Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
02:34Inhibition of CDK Activity
02:34Inhibition of Cdk Activity
01:23Dipeptidyl Peptidase 4 Inhibitors
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System